Sanofi Chimie to manufacture Pharming's Ruconest following scale-up validation
This article was originally published in Scrip
Following the recent positive opinion from the EU's CHMP for Pharming's Ruconest (recombinant human C1 inhibitor) for the treatment of angioedema attacks, the Dutch company has signed a toll manufacturing agreement with Sanofi Chimie, a wholly-owned subsidiary of Sanofi-Aventis, aimed at increasing the production capacity of the drug substance within Ruconest.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.